2,413
Participants
Start Date
July 10, 2022
Primary Completion Date
July 10, 2027
Study Completion Date
December 20, 2027
Docetaxel
75 mg/m2, d1, q3w,6 cycles
Carboplatin
AUC 6, d1, q3w,6 cycles
Trastuzumab
starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles
Pertuzumab
starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles
Nab paclitaxel
220 mg/m2, d1, q3w,6 cycles
Epirubicin
90 mg/m2, d1, q3w ,4 cycles ,followed by docetaxel
Cyclophosphamide
600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
Docetaxel
100 mg/m2, d1, q3w × 4 cycles
Epirubicin
90 mg/m2,d1, q2w × 4 cycles followed by nab-paclitaxel
Cyclophosphamide
600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
Nab paclitaxel
125 mg/m2, d1,8,15, q3w× 4 cycles
Cyclophosphamide
600 mg/m2, d1, q3w × 6 cycles
RECRUITING
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER